SBS.F · Stratec SE

-

Please sign in to comment on SBS.F

1 Comment

Admin

4 years ago

Stratec SE is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.8.

Stratec SE's total revenue rose by 17.2% to $71M since the same quarter in the previous year.

Its net income has increased by 33.4% to $10M since the same quarter in the previous year.

Finally, its free cash flow grew by 362.3% to $9M since the same quarter in the previous year.

Based on the above factors, Stratec SE gets an overall score of 4/5.

Exchange	F
CurrencyCode	EUR
ISIN	DE000STRA555
Sector	Healthcare
Industry	Medical Devices

Market Cap	276M
Beta	0.54
PE Ratio	27.68
Target Price	41
Dividend Yield	2.4%

ABOUT

Stratec SE

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

SBS.F · Stratec SE

-

Stratec SE

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Stratec SE using a moving average strategy